Terminology Service for NFDI4Health
JSON

Tesevatinib

Go to external page http://purl.obolibrary.org/obo/NCIT_C62496

An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression. [ ]

Term info

Label

Tesevatinib

Synonyms
  • 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta(c)pyrrol-5-yl)methoxy)-
  • EXEL 7647
  • KD 019
  • KD019
  • TESEVATINIB
  • Tesevatinib
  • XL647
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

CAS Registry

781613-23-8

Display Name

Tesevatinib

FDA UNII Code

F6XM2TN5A1

Has Target

http://purl.obolibrary.org/obo/NCIT_C17068, http://purl.obolibrary.org/obo/NCIT_C17293, http://purl.obolibrary.org/obo/NCIT_C17319

Preferred Name

Tesevatinib

Semantic Type

Pharmacologic Substance

UMLS CUI

C1541356

code

C62496